Fructose and the Liver.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms and prior studies without systematic review methodology or new human data.
PubMed 34203484 · doi:10.3390/ijms22136969
What was done
Narrative review summarizing preclinical and clinical evidence on the role of fructose overconsumption in the pathogenesis of metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer.
What was found
The abstract reports no quantitative data, effect sizes, or numerical values. It describes qualitative associations where fructose intake correlates with the degree of liver inflammation and fibrosis, and activates proinflammatory, fibrogenic, and oncogenic signaling pathways.
Why it matters
It emphasizes dietary fructose as a key metabolic driver in the progression from simple steatosis to hepatic fibrosis and malignancy.
Limits
Narrative review design without systematic search criteria or quantitative synthesis. No primary human data, specific intake thresholds, or patient demographics are provided in the abstract.
Cited by
- supports Non-alcoholic fatty liver disease and alcoholic liver disease share biochemical abnormalities including low AMP, high oxidative stress, and elevated uric acid.